Lupin Expects Respiratory Ramp Up From Fiscal '22
Generics To Benefit From US Election Outcome
After launching albuterol, India's Lupin is seeking to expand its presence in the respiratory market. With generic Fostair set for a European launch in fiscal 2022 and Spiriva for a US introduction the following fiscal year, the company is counting on the portfolio to deliver growth from the coming financial year.
You may also be interested in...
Appointing executives from Endo in key positions, Strides' CEO has set up a team to deliver growth, though the impact of ranitidine withdrawal and COVID-19 will defer a revenue target of $800m. Meanwhile, Stelis Biopharma signals a shift in focus from biologics development to CDMO opportunities and is poised for a stock exchange listing.
Perrigo has moved to allay more serious concerns around its generic ProAir inhaler device, but concedes that it is highly unlikely the lucrative respiratory product will return to the market this year.
Indian major Lupin is continuing to further efforts on its three main growth drivers: biosimilars, inhalation products and long-acting injectables, management told the virtual J.P. Morgan Healthcare Conference in San Francisco.